Core Viewpoint - A class action lawsuit has been filed against DexCom, Inc. alleging that the company made misleading statements regarding the reliability and safety of its G6 and G7 glucose monitoring devices, which were modified without FDA approval, leading to health risks for users [2][4]. Summary by Sections Lawsuit Details - The lawsuit claims that DexCom made unauthorized design changes to the G6 and G7 devices, which compromised their reliability and presented health risks to users [2]. - Allegations include overstating the enhancements and reliability of the G7, downplaying the severity of issues with the devices, and exposing the company to increased regulatory scrutiny and potential legal consequences [2]. Regulatory Concerns - On March 7, 2025, DexCom received a warning letter from the FDA regarding manufacturing and quality management issues, resulting in a share price drop of $7.12, or approximately 9.15%, from $77.84 to $70.72 [3]. - The FDA's published warning letter on March 25, 2025, confirmed that DexCom had adulterated its devices, leading to a further decline in share price by $1.77, or about 2.4%, from $75.32 to $73.55 [4]. Market Reactions - On September 8, 2025, Oppenheimer downgraded DexCom's rating to "perform" from "outperform," citing concerns over the G7's accuracy and performance, which caused a decline in share price by $2.51, or approximately 3.1%, from $80.51 to $78.00 [5]. - A report by Hunterbrook Media LLC on September 18, 2025, highlighted severe health risks associated with the G7 devices, linking them to hospitalizations and fatalities, resulting in a significant share price drop of $8.33, or about 11%, from $75.78 to $67.45 [7].

Group 1 - Berger Montague is advising shareholders of Baxter International Inc. regarding an investigation into the Board of Directors for potential breaches of fiduciary duties related to the marketing and sale of the Novum Large Volume Pump [1] - The investigation focuses on whether the Board of Directors properly oversaw the marketing and sale of the Novum LVP, which is used for controlled delivery of intravenous fluids [1] - In July 2025, Baxter announced a voluntary and temporary pause in shipments and planned installations of the Novum LVP [1] Group 2 - Berger Montague is a prominent law firm specializing in complex civil litigation, class actions, and mass torts, with over $2.4 billion in post-trial judgments in 2025 [1] - The firm has recovered over $50 billion for clients and represented classes in various legal areas for over 55 years [1]

New York, New York--(Newsfile Corp. - November 25, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. (NASDAQ: TNDM) resulting from allegations that Tandem Diabetes Care may have issued materially misleading business information to the investing public.SO WHAT: If you purchased Tandem Diabetes Care securities you may be entitled to compensation without payment of any out of pocket fees ...

Core Viewpoint - Labaton Keller Sucharow LLP has filed a securities class action lawsuit against DexCom, Inc. and certain executives, alleging misleading statements regarding the reliability and safety of their continuous glucose monitoring systems [1][4]. Summary by Sections Lawsuit Details - The lawsuit was filed on November 25, 2025, on behalf of the Boston Retirement System against DexCom and its executives, asserting claims under the Securities Exchange Act of 1934 [1]. - The class period for the lawsuit is defined as January 8, 2024, to September 17, 2025 [1]. Allegations - The complaint alleges that DexCom made unauthorized design changes to its CGM products, which rendered them less reliable and posed health risks to users [4]. - It is claimed that these undisclosed issues led to increased regulatory scrutiny and negatively impacted the company's sales and public statements regarding product reliability [4]. Impact on Stock Price - Following disclosures about the accuracy problems of DexCom's CGM devices, the company's stock price fell by $8.99 per share, or 11.8%, closing at $67.45 on September 19, 2025 [5]. Legal Representation - The Boston Retirement System is represented by Labaton Keller Sucharow LLP, which has a strong reputation in securities litigation and manages over $4.5 trillion in assets [8].

Core Points - Bioventus Inc. will present at the Piper Sandler Healthcare Conference on December 3, 2025, at 10:10 a.m. ET [1] - A live webcast of the presentation will be available on the company's website, with a replay option following the event [2] Company Overview - Bioventus is a global leader in innovations for active healing, providing clinically proven and cost-effective products that facilitate quick and safe healing [3] - The company's mission focuses on helping patients resume and enjoy active lives through its offerings in Pain Treatments, Restorative Therapies, and Surgical Solutions [3] - Bioventus emphasizes high quality standards, evidence-based medicine, and strong ethical behavior, positioning itself as a trusted partner for physicians worldwide [3]

Core Viewpoint - Inspire Medical Systems, Inc. is facing a class action lawsuit due to alleged securities fraud related to the poor launch of its new product, Inspire V, which was marked by significant operational failures and misrepresentations to investors [1][2]. Group 1: Lawsuit Details - The class action lawsuit seeks to recover losses for investors affected by alleged securities fraud between August 6, 2024, and August 4, 2025 [1]. - The complaint alleges that the launch of Inspire V was unsuccessful due to poor demand, with providers holding excess inventory and being hesitant to adopt the new treatment [2]. - Defendants are accused of making false statements regarding the successful launch of Inspire V, while failing to complete essential tasks such as training for treatment center customers and setting up necessary IT systems [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until January 5, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4]. - The firm has over 20 years of experience in complex securities litigation and a dedicated team of more than 70 employees [4].

Core Viewpoint - Baxter International Inc. is facing a class action lawsuit due to allegations of misleading investors regarding the safety of its Novum LVP device, which has been linked to serious malfunctions and risks to patient safety [1][3]. Summary by Sections Company Overview - Baxter International Inc. is a global company that develops, manufactures, and markets medical products used in hospitals and healthcare facilities [1]. Class Action Details - The class period for the lawsuit is from February 23, 2022, to July 30, 2025 [1]. - The lawsuit was filed on behalf of all investors who purchased or acquired Baxter's stock during this period [1]. Allegations Against Baxter - The complaint alleges that Baxter failed to disclose systemic defects in the Novum LVP device, which led to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing risks of serious injury or death to patients [3]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths but did not take adequate remedial measures [3]. - The company’s statements regarding the safety, efficacy, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [3]. Impact on Stock Price - On July 31, 2025, Baxter announced a suspension of all new Novum LVP sales, leading to a 22.4% drop in stock price, closing at $21.76 [4]. Next Steps for Shareholders - Shareholders interested in participating in the class action must submit their papers by December 15, 2025, to serve as lead plaintiff [5]. - Shareholders can remain absent class members if they choose not to participate [5].

Group 1: Market Trends and Stock Performance - Companies are benefiting from low feedstock prices and high demand for gasoline and distillates, leading to a wide crack spread that has allowed Wall Street firms to raise earnings expectations for the upcoming quarters [2] - Valero is highlighted as one of the best stocks expected to see earnings and sales acceleration in 2026 [1] - Dollar General's stock is up 39% year-to-date despite challenges faced by low-end consumers, indicating a better-than-expected performance [8] Group 2: Sector Insights - The life sciences sector is experiencing strong earnings and revenue growth due to increased capital investment in research, with several companies building positive momentum [5] - The industrial sector is anticipated to see more capital expenditures, with well-managed companies like Textron being recognized for their performance [4] - The electronic components industry is noted for steady earnings, with a focus on cyclical performance compared to larger-cap names [3] Group 3: Consumer Behavior - The low-end consumer is struggling due to inflation and rising gas prices, which is impacting companies like Dollar Tree and Dollar General, despite some stock performance improvements [7][9] - Same-store sales for low-end retailers remain muted, indicating ongoing challenges in the consumer market [9]

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? Developed alongside ...

Core Insights - The article summarizes significant research calls from Wall Street, highlighting upgrades and downgrades of various companies that could impact investor decisions [1] Upgrades - Wolfe Research upgraded Inspire Medical (INSP) to Outperform from Peer Perform with a price target of $180, citing a "surprise" 50% Medicare reimbursement increase as a positive factor for the stock [2] - UBS upgraded Cummins (CMI) to Neutral from Sell with a price target of $500, increased from $350, indicating a balanced risk/reward as the truck cycle is expected to bottom in 2026 [2] - Raymond James upgraded CDW (CDW) to Strong Buy from Outperform with a price target of $185, noting that easing cost headwinds may lead to growth acceleration [3] - Citi upgraded Brinker (EAT) to Buy from Neutral with a price target of $176, up from $144, as the cost environment improves with reduced food tariffs in Brazil, potentially boosting sales through fiscal 2026 [3] - UBS upgraded Applied Materials (AMAT) to Buy from Neutral with a price target of $285, raised from $250, based on a more optimistic outlook for wafer fab equipment spending in 2026 and 2027 [4] Downgrades - Argus downgraded Coinbase (COIN) to Hold from Buy with no price target, citing the stock's high valuation at 39 times expected forward earnings compared to lower multiples of other exchanges [5] - Rothschild & Co Redburn downgraded Estee Lauder (EL) to Sell from Neutral with a price target of $70, down from $83, due to the need for deeper investment despite improving sales growth [5] - Canaccord downgraded Exact Sciences (EXAS) to Hold from Buy with a price target of $105, up from $85, following the announcement of an acquisition agreement by Abbott (ABT) at $105 per share [5] - Northland downgraded Green Dot (GDOT) to Market Perform from Outperform with a price target of $14.25, down from $18, after the announcement of complex strategic transactions separating its fintech and bank operations [5] - Barclays downgraded Camden Property (CPT) to Equal Weight from Overweight with a price target of $118, down from $127, as its total return profile is now seen as average compared to the apartment REIT sector [5]